12 June
2024
Advanced
Medical Solutions Group plc
("AMS" or
the "Group")
Results of Annual General
Meeting
Winsford, UK: Advanced Medical
Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing
technologies, announces
that at the Company's Annual General Meeting held today at 11 am at
the Offices of Investec Bank plc, 30 Gresham Street, London,
EC2V 7QP, all resolutions were duly passed.
Further details of each of the resolutions are set
out in the Notice of Meeting, which was sent to shareholders on 13
May 2024.
The poll results were as
follows.
|
Resolution
|
Title
|
For
|
For %
|
Against
|
Against %
|
Total Votes
|
% Issued Capital
|
|
1
|
FINANCIAL STATEMENTS
|
136,356,167
|
99.99%
|
9,361
|
0.01%
|
136,365,528
|
62.69%
|
|
2
|
REMUNERATION REPORT
|
134,014,363
|
98.45%
|
2,107,730
|
1.55%
|
136,122,093
|
62.58%
|
|
3
|
AUDITOR REMUNERATION
|
133,257,997
|
97.65%
|
3,210,036
|
2.35%
|
136,468,033
|
62.74%
|
|
4
|
RE-ELECT L SHANAHAN
|
129,648,691
|
95.22%
|
6,506,705
|
4.78%
|
136,155,396
|
62.60%
|
|
5
|
RE-ELECT G COOK
|
129,863,105
|
95.16%
|
6,601,163
|
4.84%
|
136,464,268
|
62.74%
|
|
6
|
RE-ELECT D LE FORT
|
130,840,531
|
95.88%
|
5,623,737
|
4.12%
|
136,464,268
|
62.74%
|
|
7
|
RE-ELECT C MEREDITH
|
132,798,078
|
97.31%
|
3,666,187
|
2.69%
|
136,464,265
|
62.74%
|
|
8
|
RE-ELECT E JOHNSON
|
136,218,616
|
99.82%
|
245,652
|
0.18%
|
136,464,268
|
62.74%
|
|
9
|
FINAL DIVIDEND
|
136,505,565
|
100.00%
|
516
|
0.00%
|
136,506,081
|
62.76%
|
|
10
|
Deferred Bonus Plan
|
136,377,375
|
99.92%
|
113,837
|
0.08%
|
136,491,212
|
62.75%
|
|
11
|
Long Term Incentive Plan
|
135,984,889
|
99.63%
|
506,310
|
0.37%
|
136,491,199
|
62.75%
|
|
12
|
Deferred Share Bonus Plan
|
136,190,086
|
99.78%
|
300,213
|
0.22%
|
136,490,299
|
62.75%
|
|
13
|
ALLOT SHARES*
|
135,883,826
|
99.56%
|
600,189
|
0.44%
|
136,484,015
|
62.75%
|
|
14
|
PRE-EMPTION RIGHTS*
|
134,775,458
|
98.75%
|
1,708,671
|
1.25%
|
136,484,129
|
62.75%
|
|
15
|
PURCHASE SHARES*
|
108,148,575
|
99.92%
|
82,427
|
0.08%
|
108,231,002
|
49.76%
|
* Special
Resolution
|
Notes:
1. Votes "For" and "Against"
are expressed as a percentage of votes received.
2. A "Vote withheld" is not a
vote in law and is not counted in the calculation of the votes
"For" or "Against" a resolution.
3. Total number of shares in
issue at close of business on 7 June = 217,508,089 shares. 62.75% of the
voting capital was instructed.
|
- End -
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott
/ Lucy Featherstone
|
AMS@icrhealthcare.com
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
|
|
|
HSBC Bank plc (Broker)
|
Tel: 44
(0) 20 7991 8888
|
|
Sam McLennan / Joe Weaving /
Stephanie Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®,
RESORBA®, LiquiBandFix8® and
Seal-G®. AMS also supplies wound care dressings such as
silver alginates, alginates and foams through its
ActivHeal® brand as well as under white label.
Since 2019, the Group has made six acquisitions: Sealantis, an
Israeli developer of innovative internal sealants; Biomatlante, a
French developer and manufacturer of surgical biomaterials,
Raleigh, a leading UK coater and converter of woundcare and
bio-diagnostics materials, AFS Medical, an Austrian specialist
surgical business, Connexicon, an Irish tissue adhesives
specialist, and Syntacoll, a German
specialist in collagen-based absorbable surgical
implants.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, the Czech Republic and
Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct
sales forces in the UK, Germany, the Czech Republic and Russia. The
Group has R&D innovation hubs in the UK, Ireland, Germany,
France and Israel. Established in 1991, the Group has more than 900
employees. For more information, please see www.admedsol.com.